WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2022 , the compensation committee of the Company’s Board of Directors approved grants of
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 31, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Dr. Anna Berkenblit , Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel
Submission Based on Positive Results from Pivotal Phase 3 SORAYA Trial WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 29, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has submitted a Biologics
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9 Months Mirvetuximab Demonstrated Meaningful Anti-Tumor Activity, Consistent Safety, and Favorable Tolerability in FRα-High Platinum-Resistant
Data from Pivotal Trial to be Highlighted in Oral Presentation on Saturday, March 19 Investor Event to be Held Sunday, March 20 at 7:30 am MST WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 10, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 28, 2022 , the compensation committee of the Company’s Board of Directors approved grants
Positive Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer; Detailed Results to be Presented in Plenary Session at SGO in March Mirvetuximab BLA On Track for Submission this Quarter IMGN632 Triplet Data Demonstrating Manageable Safety Profile and Encouraging
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will participate in the ovarian cancer panel discussion at the
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform ImmunoGen to Receive a $13 Million Upfront Payment for Initial Targets; Eligible to Receive an Additional $32.5
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 10, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its